Revive Therapeutics Ltd. · CSE:RVV

Revive Therapeutics — Investor Presentation (April 2020)

17 slides from Revive Therapeutics's investor presentation, April 2020

  1. Slide 1: A Specialty Life Sciences Company

    Slide 1: A Specialty Life Sciences Company

    A Specialty Life Sciences Company Corporate Presentation April 2020 Revive Therapeutics Ltd. | Office: 1-888-901-0036 | E-mail: mfrank@revivethera.com

  2. Slide 2: Forward Looking Statements

    Slide 2: Forward Looking Statements

    FORWARD LOOKING STATEMENTS Certain statements contained in this presentation constitute forward-looking information within the meaning of securities laws. Forward- looking information may relate to our future outlook and anticipated events or results and may include statements regarding our future f

  3. Slide 3: Revive Therapeutics

    Slide 3: Revive Therapeutics

    REVIVE THERAPEUTICS § Specialty life sciences company focused on repurposing drugs for rare disorders and infectious diseases § Developing novel Psiliocybin and Cannabidiol therapeutics for various CNS and inflammatory disorders § Advancing clinical development of Bucillamine for infectious diseases

  4. Slide 4: Pharmaceutical Strategy

    Slide 4: Pharmaceutical Strategy

    PHARMACEUTICAL STRATEGY Clinical development of Targeting Rare Disorders Novel Uses, Targeting FDA Designations: Psilocybin, Cannabidiol and Infectious Diseases Formulations, and Orphan, Fast track, and Bucillamine Delivery System Breakthrough therapy and Rare pediatric diseases

  5. Slide 5: Patent Portfolio

    Slide 5: Patent Portfolio

    PATENT PORTFOLIO Title USPTO No. Status Use of Bucillamine in the Treatment of Infectious Diseases, including COVID-19 62/991,996 Provisional patent filed Use of Bucillamine in the Treatment of Gout US9662305 Issued on May 30, 2017 US 8642088 Issued on February 4, 2014 Cannabinoid Delivery System US

  6. Slide 6: Formulation & Delivery Technology

    Slide 6: Formulation & Delivery Technology

    FORMULATION & DELIVERY TECHNOLOGY § Delivering naturally extracted and synthetic psilocybin and cannabinoids § PSILOCYBIN - Precise dosed formulations i.e. capsules, sublingual spray, gel caps, effervescent tablets and oral/transmucosal strips § Releases (rapid, controlled, sustained), improved bioa

  7. Slide 7: Product Pipeline

    Slide 7: Product Pipeline

    PRODUCT PIPELINE Focus on Infectious Diseases, including COVID-19, and Rare Disorders Stage of Regulatory Product Indication Market Development Status Infectious Diseases Received FDA Bucillamine Filing IND TBD (COVID-19) Orphan Status Liver Diseases Received FDA + $100M CBD Filing IND (Autoimmune H

  8. Slide 8: Infectious Disease Opportunity

    Slide 8: Infectious Disease Opportunity

    INFECTIOUS DISEASE OPPORUNTIY § Focus on Bucillamine in the treatment of infectious diseases § Well-known safety profile and prescribed for arthritis in Japan and South Korea for over 30 years § Revive’s clinical history with Bucillamine § Obtained 2 FDA INDs with Bucillamine and FDA orphan drug sta

  9. Slide 9: Liver Disease Opportunity

    Slide 9: Liver Disease Opportunity

    LIVER DISEASE OPPORTUNITY § Focus on Autoimmune Hepatitis (AIH) § AIH - rare disease (~ 76k patients in US) causing liver inflammation • Drawbacks of current therapies (steroids): Severe side effects in 13%, relapse after drug withdrawal in 50%-86%* § Obtained FDA orphan drug status for CBD in the t

  10. Slide 10: Psychedelic Opportunity

    Slide 10: Psychedelic Opportunity

    PSYCHEDELIC OPPORTUNITY § Acquired Psilocin Pharma Corp. § Derrick Welch, Founder with 14 years of HC experience; 5 years in Cannabis § Worked with Xanthic Bio Pharma and Green Growth Brands § Developed water Soluble THC and CBD products (Beverages, effervescent tablets) § Novel Psilocybin formulati

  11. Slide 11: Strategic Partners

    Slide 11: Strategic Partners

    STRATEGIC PARTNERS Infectious Diseases Acquired March 2020 Supply and collaboration CRO Psychedelic pharma of truffles License of cannabidiol for License of cannabinoid Research collaboration treatment of Autoimmune delivery technology for liver diseases Hepatitis

  12. Slide 12: Value Driving Milestones in 2020

    Slide 12: Value Driving Milestones in 2020

    VALUE DRIVING MILESTONES IN 2020 Q2 Submit IND for Phase 2 clinical study of Bucillamine in the treatment of COVID-19 Q2 Initiate Phase 2 clinical study of Bucillamine in the treatment of COVID-19 Q2 Submit IND for Phase 2 clinical study of CBD in the treatment of Autoimmune Hepatitis Q2/3 Pre-IND m

  13. Slide 13: Significantly Undervalued

    Slide 13: Significantly Undervalued

    SIGNIFICANTLY UNDERVALUED 24 M

  14. Slide 14: Organization

    Slide 14: Organization

    ORGANIZATION Management Board of Directors § Michael Frank § Michael Frank Chairman and CEO Chairman and CEO § Carmelo Marrelli § William Jackson Chief Financial Officer Director § Joshua Herman Clinical Director § Dr. Kelly McKee, Jr., MD, MPH § Christian Scovenna Chief Scientific Officer, Consulta

  15. Slide 15: Stock Information

    Slide 15: Stock Information

    STOCK INFORMATION Ticker RVV (CSE) Share Price CAD $0.125 (April 17, 2020) 52 week High/Low CAD $0.155 / $0.025 Capital Structure 189,408,777 common shares (267,075,486 fully-diluted) Market Cap CAD ~ $23,500,000

  16. Slide 16: Appendix – Bucillamine Scientific Rationale for COVID-19

    Slide 16: Appendix – Bucillamine Scientific Rationale for COVID-19

    Appendix – Bucillamine Scientific Rationale for COVID-19 Current antiviral interventions for influenza have exhibited modest efficacy, especially in improving mortality in at-risk populations, such as the elderly.1,2 Novel antivirals have been plagued by poor oral bioavailability and lack of efficac

  17. Slide 17: Appendix – Bucillamine Scientific Rationale for COVID-19 (References)

    Slide 17: Appendix – Bucillamine Scientific Rationale for COVID-19 (References)

    Appendix – Bucillamine Scientific Rationale for COVID-19 References 1. Muthuri SG, Venkatesan S, Myles PR et al. Effectiveness of neuraminidase inhibitors in reducing mortality in patients admitted to hospital with influenza A H1N1pdm09 virus infection: a meta-analysis of individual participant data

Source: Internet Archive copy of revivethera.com

More decks from Revive Therapeutics Ltd.

All 36 Revive Therapeutics decks